Université de Lorraine, CHU de Nancy, Hepatogastroenterology Department, Nancy, France; Université de Lyon, Hospices Civils de Lyon, Hospital E. Herriot, Digestive Physiology Department, Lyon, France.
Université de Lyon, Hospices Civils de Lyon, Hospital E. Herriot, Digestive Physiology Department, Lyon, France.
Clin Res Hepatol Gastroenterol. 2024 Oct;48(8):102440. doi: 10.1016/j.clinre.2024.102440. Epub 2024 Aug 5.
Peroral endoscopic myotomy (POEM) has become the first line treatment for achalasia, but controversies remain about the prevalence of gastro-esophageal reflux disease (GERD) after the procedure. The aim of this study was to evaluate post-POEM GERD by a retrospective analysis of a single center cohort.
Achalasia patients aged 18 or above, who underwent POEM between 2012 and 2021, were included, provided they had an endoscopic control of reflux at least one year after POEM. GERD symptoms based on GerdQ questionnaire, and proton pomp inhibitors (PPI) consumption were also evaluated.
Among a consecutive cohort of 422 patients treated by POEM, 254 patients were included. Endoscopic results were available after a mean follow-up of 1.9 ± 1.5 years. 71/254 patients (28 %) had erosive esophagitis (86 % Los Angeles Grade A or B). At the last follow-up (mean 4.5 ± 2.2 years), clinical success of POEM (Eckardt score ≤ 3) was achieved in 79.5 % of patients. 44.5 % of patients were on PPI. Mean GerdQ score was 2.2 ± 2.7, with only 13 patients (6.5 %) with a score ≥ 8.
In this cohort of achalasia patients with an endoscopic follow-up at least 1 year after POEM, GERD did not appear a major threat concern: clinical symptoms were mild in most cases, as was the degree of erosive esophagitis. Furthermore, at the time of last follow up, less than half of patients required treatment with PPI.
经口内镜下肌切开术(POEM)已成为贲门失弛缓症的首选治疗方法,但关于该手术后胃食管反流病(GERD)的发生率仍存在争议。本研究旨在通过对单中心队列的回顾性分析来评估 POEM 术后的 GERD。
纳入年龄在 18 岁及以上、2012 年至 2021 年期间接受 POEM 治疗的贲门失弛缓症患者,只要 POEM 后至少有一次内镜反流控制即可。根据 GerdQ 问卷评估 GERD 症状和质子泵抑制剂(PPI)的使用情况。
在接受 POEM 治疗的连续队列中,共有 422 例患者,其中 254 例患者纳入研究。在平均 1.9±1.5 年的随访后,获得了内镜结果。71/254 例(28%)患者存在糜烂性食管炎(86%洛杉矶 A 或 B 级)。在最后一次随访(平均 4.5±2.2 年)时,79.5%的患者达到了 POEM 的临床成功(Eckardt 评分≤3)。44.5%的患者服用 PPI。平均 GerdQ 评分为 2.2±2.7,仅有 13 例(6.5%)患者的评分≥8。
在本贲门失弛缓症患者队列中,POEM 术后至少有 1 年的内镜随访结果显示,GERD 似乎不是一个主要的威胁:大多数情况下,临床症状较轻,糜烂性食管炎的程度也较轻。此外,在最后一次随访时,不到一半的患者需要用 PPI 治疗。